|
The 3rd quarter revenue reached 113.7 billion won, marking a 15% increase year-on-year
2020.11.11
|
|---|
|
In 3Q 2020, Daehan New Pharm achieved a cumulative operating profit of 19.6 billion won with an operating margin of 17%, representing a 21% increase compared to the same period last year. Revenue grew 15% to 113.7 billion won, and net profit reached 6.3 billion won.
The quarterly performance also showed growth momentum. Operating profit for 3Q rose 40% year-on-year to 7.4 billion won, while revenue increased 23% to 39.5 billion won.
The growth was driven by a broad increase in product sales. The company launched "Fine S Tablet," a cold and allergic rhinitis medicine with bromelain as the main ingredient, and expanded sales of "Luthione Tablet," containing glutathione, well known for its use in whitening injections.
Moreover, despite the challenges posed by the COVID-19 situation, the company has actively pursued research and development efforts.
This overview reflects Daehan New Pharm’s strong financial performance and commitment to innovation during this period. |


Home